Myriad Advances MRD Commercialization Timeline, Bolstered by New Study Data
2 Healthcare Stocks with Solid Fundamentals and 1 That Underwhelm [Yahoo! Finance]
Myriad Genetics (NASDAQ:MYGN) was downgraded by analysts at Zacks Research from a "hold" rating to a "strong sell" rating.
Myriad Genetics Q4 and 2025 revenue ranges include consensus [Seeking Alpha]
Myriad Genetics Announces Select Preliminary Fourth Quarter and Full Year 2025 Financial Results and Introduces Full Year 2026 Financial Guidance